A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs INCB 086550 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 19 Jun 2019 Planned number of patients changed from 57 to 70.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.
- 11 Dec 2018 New trial record